Western Wheatgrass Solution
NDC Package 22840-1237-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Western Wheatgrass (pascopyrum smithii) solution is allergenic Extracts are indicated for the diagnosis and treatment of patients with immediate hypersensitivity allergy to the respective allergens, inhaled, ingested or otherwise introduced into contact with sensitive tissues. This formulation utilizes a solution delivery system. Marketed by Greer Laboratories, Inc., this product is identified by NDC 22840-1237 and is authorized under FDA application BLA101833.

Identification & Billing

NDC Package Code
22840-1237-2
Package Description
10 mL in 1 VIAL, MULTI-DOSE
Product Code
22840-1237
11-Digit Billing Format
22840123702
RxNorm Crosswalk
  • RxCUI: 1013966 - canary grass pollen extract 20,000 UNT/mL Injectable Solution
  • RxCUI: 1013966 - canary grass pollen extract 20000 UNT/ML Injectable Solution
  • RxCUI: 1013966 - Phalaris arundinacea pollen extract 20,000 UNT/ML Injectable Solution
  • RxCUI: 1014343 - Italian rye grass pollen extract 50 MG/mL Injectable Solution
  • RxCUI: 1014343 - Italian rye grass pollen extract 50 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Western Wheatgrass
Non-Proprietary Name
Pascopyrum Smithii
Substance Name
Pascopyrum Smithii Pollen
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
  • Intradermal - Administration within the dermis.
  • Percutaneous - Administration through the skin.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
PASCOPYRUM SMITHII POLLEN 20000 [PNU]/mL
Pharmacologic Class
Usage Information
Allergenic Extracts are indicated for the diagnosis and treatment of patients with immediate hypersensitivity allergy to the respective allergens, inhaled, ingested or otherwise introduced into contact with sensitive tissues. The diagnosis of IgE‑mediated allergy may be established by the allergy history, clinical evaluation, and skin test reactivity. (4,7,11) Immunotherapy with Allergenic Extracts is indicated when testing and patient history have identified the offending allergens and when it is not possible or practical to avoid these allergens. (12‑14) Food extracts have not been proven effective in immunotherapy. The use of Allergenic Extracts for the above purposes should be made only by physicians with special familiarity and knowledge of allergy. (See DOSAGE AND ADMINISTRATION)

Regulatory & Marketing

Labeler Name
Greer Laboratories, Inc.
Product Type
Non-standardized Allergenic
FDA Application #
BLA101833
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-15-1981
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 22840-1237-2 identifies a specific commercial package of 10 ml in 1 vial, multi-dose of Western Wheatgrass, a non-standardized allergenic label labeled by Greer Laboratories, Inc.. This solution is formulated for intradermal; percutaneous; subcutaneous use and contains pascopyrum smithii pollen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Greer Laboratories, Inc. on September 15, 1981. The current certification is valid through December 31, 2026.

How is this Greer Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 22840123702. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
22840-1237-2
11-Digit CMS (5-4-2)
22840-1237-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.